Claims
- 1. A method of topical treatment of an inflammatory condition of the skin comprising applying to the affected area a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of arylacetohydroxamic acids of the formula ##STR1## wherein R and R' represent an alkyl C.sub.1 -C.sub.6, cycloalkyl C.sub.5 -C.sub.6, alkoxy C.sub.1 -C.sub.6, alkenyloxy C.sub.5 -C.sub.6, cycloalkenyloxy C.sub.5 -C.sub.6, alkylthio C.sub.1 -C.sub.6, cycloalkyloxy C.sub.5 -C.sub.6, cycloalkylalkyloxy (with cycloalkyl C.sub.5 -C.sub.6 and alkyl C.sub.1 -C.sub.6), or arylalkyloxy C.sub.1 -C.sub.6 radical, R and R' can be the same or different, R' can also be hydrogen, and n has a value of 0 to 2, and, concurrent therewith, a topically active anti-inflammatory corticosteroid, each of said prostaglandin synthetase inhibitor and said corticosteroid being applied in a pharmaceutically acceptable topical vehicle, the amounts of said anti-inflammatory drugs being sufficient in combination to combat said inflammatory condition.
- 2. The method of claim 1 wherein said topical vehicle comprises a mixture of propylene glycol and ethanol.
- 3. The method of claim 1 wherein said topical vehicle comprises a mixture of propylene glycol and dimethylsulfoxide.
- 4. The method of claim 2 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said topically active corticosteroid comprising from about 0.01% to about 0.5% by weight of triamcinolone acetonide.
- 5. A method of treating inflammatory conditions of the skin which comprises topically applying to the affected area the composition of claim 4.
- 6. The method of claim 1 wherein said substituted arylacetohydroxamic acid is bufexemac.
- 7. The method of claim 1 wherein said substituted arylacetohydroxamic acid is bufexemac.
- 8. A composition for the topical treatment of an inflammatory condition of the skin comprising a pharmaceutically acceptable topical vehicle containing a non-steroidal a inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of an acyl acetohydroxamic acid of the formula ##STR2## wherein R and R' represent alkyl C.sub.1 -C.sub.6, cycloalkyl C.sub.5 -C.sub.6, alkoxy C.sub.1 -C.sub.6, alkenyloxy C.sub.5 -C.sub.6, cycloalkenyloxy C.sub.5 -C.sub.6, alkylthio C.sub.1 -C.sub.6, cycloalkyloxy C.sub.5 -C.sub.6, cycloalkylakyloxy C with cycloalkyl C.sub.5 -C.sub.6 and alkyl C.sub.1 -C.sub.6, or arylalkyloxy C.sub.1 -C.sub.6 radical, R and R' can be the same or different, R' can also be hydrogen, and n has a value of 0 to 2, and a topically active anti-inflammatory corticosteroid, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
- 9. The composition of claim 8 wherein said topical vehicle comprises a mixture of propylene glycol and ethanol.
- 10. The composition of claim 8 wherein said topical vehicle comprises a mixture of propylene glycol and dimethylsulfoxide.
- 11. The composition of claim 9 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said composition further comprising from about 0.01% to about 0.5% by weight of triamcinolone acetonide.
- 12. The composition of claim 10 wherein said concentration is from about 0.05% to about 0.1%.
- 13. The composition of claim 10 wherein said concentration is from about 2% to about 5%.
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a division of application Ser. No. 442,997, filed Nov. 19, 1982 now U.S. Pat. No. 4,473,565 which is a continuation-in-part of our copending application Ser. No. 685,942, filed May 13, 1976, now abandoned.
Divisions (1)
|
Number |
Date |
Country |
Parent |
442997 |
Nov 1982 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
685942 |
May 1976 |
|